Johnson & Johnson has kicked off the interim results season with a warning that low-cost generic and biosimilar competition is ramping up its pharma business.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,